Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Status:
Completed
Trial end date:
2020-05-27
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of IL-2 and the highest dose of
this drug that can be given safely to people with chronic graft versus host disease (GVHD).
Chronic GVHD is a medical condition that may occur after patients receive a bone marrow, stem
cell or cord blood transplant. The donor's immune system may recognize their body (the host)
as foreign and attempt to "reject" it. Traditional standard therapy to treat chronic GVHD is
prednisone (steroids). Treatment options are limited, and it is thought that IL-2 may help to
control chronic GVHD.